Inovio Says Study Shows Robust Vaccine Antibody Response; Positive Results on Leukemia DNA Vaccine
Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that preliminary results of a phase II clinical trial to treat leukemia with a WT1 DNA vaccine delivered with Inovio's proprietary electroporation delivery system showed robust vaccine-specific antibody responses in all vaccinated subjects evaluated to date. Furthermore, T cell immune responses, including those of the "killer T cells," were detected. Antibody and T cell responses are strong signals of the DNA vaccine's potential to treat the disease.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.